Highlights:

• Revenue reached AU$3.32 billion, supported by strong organic growth across key operations.
• Underlying NPAT surged 25.8%, reinforcing ALS’s record earnings performance.
• ALS reached its FY27 financial objectives a full year earlier than planned.

ALS Limited (ASX: ALQ) delivered a record FY26 performance, with its annual financial report signed on 18 May 2026 for the year ended 31 March 2026. The global testing and analytical services group reported strong revenue and profit growth, supported by higher minerals-testing volumes, improved pricing and disciplined cost management. Notably, ALS reached its FY27 financial goals twelve months earlier than anticipated.Record Earnings MomentumRevenue from continuing operations increased 10.7% to AU$3.32 billion, including organic growth of 8.4%. Underlying EBIT advanced 19.3% to AU$599.0 million, while underlying NPAT climbed 25.8% to AU$381.2 million. Statutory NPAT also rose 24.4% to AU$318.7 million. 

Cash generation remained healthy, with net free cash flow before capital expenditure reaching AU$674.1 million and EBITDA cash conversion at 92%. ALS also reduced leverage to 1.5 times, enhancing financial flexibility. Minerals Drives GrowthCommodities remained the standout performer. Organic revenue increased 18.1%, while Minerals delivered 20.2% organic growth and closed FY26 with an EBIT margin of 33.0%. Stronger sample volumes, improved second-half pricing and supportive critical-minerals activity helped lift profitability. 

Life Sciences produced a more measured performance, with organic revenue growth of 2.8%. Food expanded 7.2%, while Environmental faced weaker conditions in the Americas and integration challenges at York. Meanwhile, the Nuvisan restructuring concluded with annualised cost savings of approximately €25 million at exit. Dividend and InvestmentThe stronger result supported a 23.1-cent final dividend, lifting the FY26 total to 42.5 cents per share, up 10.1% from FY25. ALS is simultaneously investing in automation, robotics, AI-enabled solutions and laboratory capacity to improve productivity and support future expansion. 

What Comes Next?With its previous FY27 financial targets already achieved, ALS enters its next phase from a stronger earnings and balance-sheet position. Management continues to target mid-to-high single-digit organic revenue growth, progressive margin improvement and stronger returns on capital. 

The key test will be whether Minerals can sustain elevated growth while Life Sciences improves across weaker markets. If laboratory investment, automation and operational leverage deliver as planned, ALS has multiple avenues to extend its earnings trajectory beyond FY26.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au